Human metapneumovirus: the hidden viral menace making headlines

Human metapneumovirus (HMPV) is a significant contributor to acute respiratory tract infections (ARIs), a leading global cause of morbidity and mortality, particularly in children under five years old. Discovered in 2001 in the Netherlands, HMPV is a member of the paramyxoviridae family and exists as two genotypes (A and B) with further subdivisions. Its prevalence is global, with seasonal outbreaks occurring predominantly in spring and winter. By the age of 5-10 years, most children have been exposed, but re-infections can occur throughout life due to incomplete immunity. HMPV infections primarily present as bronchiolitis, pneumonia and wheezing with more severe outcomes in infants, the elderly and immunocompromised individuals. The virus is challenging to diagnose due to its slow growth in cell culture, with RT-PCR and immunofluorescence assays being the most reliable diagnostic tools. Differential diagnosis includes other respiratory viruses such as RSV, influenza and bacterial pathogens. Treatment options remain limited to supportive care, through experimental therapies like ribavirin and fusion inhibitors show promise in preclinical studies. Prevention strategies focus on hygiene measures such as handwashing, mask usage and environmental disinfection, along with strict infection control protocols in healthcare settings. Despite its significant health burden, no licensed vaccines or antiviral treatments are available. Public health efforts emphasize the need for active surveillance, public education and research into effective vaccines and therapies. This review highlights the epidemiology, clinical manifestations, diagnostic challenges and prevention strategies of HMPV, emphasizing the need for targeted interventions to mitigate its global impact.